에스엘에스바이오 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 이영태, was filed 18 Dec 2024.
에스엘에스바이오: what insiders have been doing
에스엘에스바이오 is a Health Care company. Its directors and officers file their transactions with DART (FSS). Between 1 November 2025 and 1 November 2026, 1 insider published 1 filing.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
For context, the typical company on the same exchange (median of 2,655 companies) published 7 filings over the same period, against 1 filing here. Over the whole record (from 2021), the tally stands at 13 purchases and 2 sales.
Over the last twelve months, not one insider purchase of 에스엘에스바이오 stock was filed.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Who traded when
BuySaleSince the insiders bought
- -29.6%Entry ₩2,438 · Close at T+365 ₩1,715
- -28.4%Entry ₩2,500 · Close at T+365 ₩1,789
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- ●Executives0DART
- 450,000 sharesShareKRXDART:20250311001256
- ●Executives0DART
- 3,089,546 sharesKRXDART:20241218000118Canonical exit: 16 Mar 2025 (T+90)
- ShareKRXDART:20240723000108Canonical exit: 13 Oct 2024 (T+90)
- ShareKRXDART:20240723000109Canonical exit: 15 Oct 2024 (T+90)
- ●Executives0DART
- ShareKRXDART:20240718000035Canonical exit: 13 Oct 2024 (T+90)
- ShareKRXDART:20240718000040Canonical exit: 13 Oct 2024 (T+90)
- ShareKRXDART:20240718000063Canonical exit: 28 Apr 2024 (T+90)
- 10,900 sharesKRXDART:20240703000078Canonical exit: 30 Sept 2024 (T+90)
- 2,000 shares@ ₩4,967.00100.0% of flowShareKRXDART:20240208000112Canonical exit: 5 May 2024 (T+90)
- 6,000 shares@ ₩5,256.6667100.0% of flowShareKRXDART:20240206000611Canonical exit: 2 May 2024 (T+90)
- 41,740 sharesKRXDART:20240205000281Canonical exit: 30 Apr 2024 (T+90)
- ShareKRXDART:20231020000426
- ShareKRXDART:20231020000251
- ShareKRXDART:20231020000236
- 10,900 sharesKRXDART:20231020000240Canonical exit: 12 Jan 2024 (T+90)
- 230,455 sharesKRXDART:20230303000398
- 10,900 sharesKRXDART:20220908000537Canonical exit: 7 Dec 2022 (T+90)
- ShareKRXDART:20211230000438
- 10,900 sharesKRXDART:20211230000424Canonical exit: 30 Mar 2022 (T+90)
- ShareKRXDART:20210514000607
23 of 23 declarations
About 에스엘에스바이오
SLS Bio is a company operating in the health and pharmaceutical sector, listed on the XKRX. It focuses on developing innovative biological solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
